<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27270345</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Current opinion in rheumatology</Title><ISOAbbreviation>Curr Opin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.</ArticleTitle><Pagination><StartPage>453</StartPage><EndPage>459</EndPage><MedlinePgn>453-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOR.0000000000000308</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Cutaneous lupus erythematosus (CLE) is a common manifestation among systemic lupus patients. There are no U.S. Food and Drug Administration approved therapies for CLE, and these lesions are frequently disfiguring and refractory to treatment. The present review will cover the recent inroads made into understanding the mechanisms behind CLE lesions and discuss promising therapeutic developments.</AbstractText><AbstractText Label="RECENT FINDINGS">The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols. Research into the pathogenesis of CLE is accelerating, and discoveries are now identifying genetic and epigenetic changes which may predispose to particular disease manifestations. Furthermore, unique features of disease subtypes are being defined. Murine work supports a connection between cutaneous inflammation and systemic lupus disease activity. Importantly, human trials of type I interferon blockade hold promise for improving our treatment armamentarium for refractory CLE lesions.</AbstractText><AbstractText Label="SUMMARY">Continued research to understand the mechanisms driving CLE will provide new methods for prevention and treatment of cutaneous lesions. These improvements may also have important effects on systemic disease activity, and thus, efforts to understand this link should be supported.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stannard</LastName><ForeName>Jasmine N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>aDivision of Rheumatology, Department of Internal Medicine bDivision of Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahlenberg</LastName><ForeName>J Michelle</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AR063668</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AR066337</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Rheumatol</MedlineTA><NlmUniqueID>9000851</NlmUniqueID><ISSNLinking>1040-8711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C431713">IRF5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013473">Sunscreening Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439524">TNF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W5C518302</RegistryNumber><NameOfSubstance UI="D003622">Dapsone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053634">TYK2 Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="C070139">TYK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>H0C805XYDE</RegistryNumber><NameOfSubstance UI="D011796">Quinacrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>LDO2FIQ61I</RegistryNumber><NameOfSubstance UI="C577244">rontalizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>XOY1YA7RMC</RegistryNumber><NameOfSubstance UI="C568334">sifalimumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003622" MajorTopicYN="N">Dapsone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050835" MajorTopicYN="N">Interferon Regulatory Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="N">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011796" MajorTopicYN="N">Quinacrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013473" MajorTopicYN="N">Sunscreening Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053634" MajorTopicYN="N">TYK2 Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27270345</ArticleId><ArticleId IdType="mid">NIHMS795478</ArticleId><ArticleId IdType="pmc">PMC4965280</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000308</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mikita N, et al. Recent advances in cytokines in cutaneous and systemic lupus erythematosus. J Dermatol. 2011;38(9):839&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">21767292</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen LK, Davis MD. Prevalence of Skin and Skin-Related Diseases in the Rochester Epidemiology Project and a Comparison with Other Published Prevalence Studies. Dermatology. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061335</ArticleId><ArticleId IdType="pubmed">27011206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">7229150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26872954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A, Chong BF. Photosensitivity in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2013;29(1):4&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539182</ArticleId><ArticleId IdType="pubmed">23281691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronhagen CM, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">21574972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek IT, et al. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014;150(3):291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">24477339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, et al. Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol. 2000;136(8):1033&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz HY, et al. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol. 2015;135(1):7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4921244</ArticleId><ArticleId IdType="pubmed">25501376</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmola A, et al. Genetic background of cutaneous forms of lupus erythematosus: update on current evidence. J Appl Genet. 2004;45(1):77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960770</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer GF, et al. Association between chronic cutaneous lupus erythematosus and HLA class II alleles. Hum Immunol. 1994;41(4):280&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7883595</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, et al. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000;115(4):726&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998151</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow YJ, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A(2):296&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382202</ArticleId><ArticleId IdType="pubmed">25604658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbari A, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134(1):87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858414</ArticleId><ArticleId IdType="pubmed">23771123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foering K, et al. Characterization of clinical photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol. 2013;69(2):205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928014</ArticleId><ArticleId IdType="pubmed">23648190</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa F, et al. Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol. 1999;118(1):164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1905409</ArticleId><ArticleId IdType="pubmed">10540174</ArticleId></ArticleIdList></Reference><Reference><Citation>Toberer F, et al. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray. Exp Dermatol. 2013;22(10):656&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">24079735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54(3):939&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">16511837</ArticleId></ArticleIdList></Reference><Reference><Citation>Reefman E, et al. Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? Arthritis Res Ther. 2006;8(6):R156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794497</ArticleId><ArticleId IdType="pubmed">17014704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, et al. C1q protein binds to the apoptotic nucleolus and causes C1 protease degradation of nucleolar proteins. J Biol Chem. 2015;290(37):22570&#x2013;22580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4566231</ArticleId><ArticleId IdType="pubmed">26231209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansel JC, et al. Effects of UV radiation on autoimmune strains of mice: increased mortality and accelerated autoimmunity in BXSB male mice. J Invest Dermatol. 1985;85(3):181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">3897390</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokogawa M, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014;66(3):694&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">24574230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashir MM, Sharma MR, Werth VP. UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription. J Invest Dermatol. 2009;129(4):994&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345265</ArticleId><ArticleId IdType="pubmed">19005488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerl V, et al. The intracellular 52-kd Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I. Arthritis Rheum. 2005;52(2):531&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15692985</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Q, et al. Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin. Autoimmunity. 2014;47(3):185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">24328602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum. 2008;58(10):3205&#x2013;3215.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. 2011;187(11):6143&#x2013;6156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221936</ArticleId><ArticleId IdType="pubmed">22058412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YJ, et al. Disease association of the interleukin-18 promoter polymorphisms in Taiwan Chinese systemic lupus erythematosus patients. Genes Immun. 2007;8(4):302&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685590</ArticleId></ArticleIdList></Reference><Reference><Citation>Biazar C, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Autoimmun Rev. 2013;12(3):444&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">23000206</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PH, et al. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. Rheumatology (Oxford) 2013;52(2):337&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">23038697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.</Citation><ArticleIdList><ArticleId IdType="pubmed">19821298</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich A, et al. Treatment of cutaneous lupus erythematosus: current practice variations. Lupus. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26821963</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol. 2013;6(1):27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543290</ArticleId><ArticleId IdType="pubmed">23320123</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila LM, et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. P R Health Sci J. 1999;18(2):89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10461313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011;65(6):e179&#x2013;e193.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007;156(1):191&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17199600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigges J, et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013;12(7):694&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">23220353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16029342</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18(2):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9782534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter A, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156(6):1321&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">17408395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(4):717&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641078</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol. 1985;121(10):1323&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">4037829</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol. 1986;122(4):376&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">3954403</ArticleId></ArticleIdList></Reference><Reference><Citation>McCune WJ, Gonzalez-Rivera T. Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity? Curr Opin Rheumatol. 2015;27(3):213&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">25784384</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AY, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282057</ArticleId><ArticleId IdType="pubmed">21768444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE) Ann Rheum Dis. 2016;75(1):196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">26038091</ArticleId></ArticleIdList></Reference><Reference><Citation>Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18(2):92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22334272</ArticleId></ArticleIdList></Reference><Reference><Citation>Husein-ElAhmed H, et al. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatol Venereol Leprol. 2014;80(5):477&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">25201862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>